US nutritional group Abbott has booked a slide in third-quarter sales from its baby-food division thanks to September’s recall of Similac infant formula.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

For the three months to the end of September, sales from Abbott’s pediatric nutritionals division dropped 9.3% to US$679m. For the nine-month period, sales slid 4.5% to $905m.

Last month, Abbott said it would pull millions of containers of its Similac-brand infant formula after beetles were found in its products and in one plant where the product is made.

Overall, however, Abbott said it delivered a “strong” performance in the quarter and confirmed a forecast of double-digit profit growth for the full year.

“The strategic actions we’ve taken across our global businesses position us well in high-growth emerging markets as well as promising new therapeutic areas,” said Miles White, chairman and CEO of Abbott.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

For the full earnings statement from Abbott, click here.

Just Food Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Just Food Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving food industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now